Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur Urol 2013;64:517-8.

European Urology

Volumn 65, Issue 1, 2014, Pages

  Cronauer, Marcus V ^a   Schrader, Mark G ^a   Schrader, Andres J ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTIANDROGEN; CORTICOSTEROID; CORTICOTROPIN; CYP17A1 INHIBITOR; CYTOCHROME P450 INHIBITOR; ENZALUTAMIDE; GALETERONE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ABIRATERONE ACETATE WITHDRAWAL; ANDROGEN SYNTHESIS; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CORTICOTROPIN RELEASE; CROSS RESISTANCE; GENE MUTATION; HUMAN; IN VITRO STUDY; LETTER; LIGAND BINDING; PRIORITY JOURNAL; RNA SPLICING; WITHDRAWAL SYNDROME; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

ANDROGEN ANTAGONISTS; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 84888824039     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.08.035     Document Type: Letter

References (8)

1. J.A. Witjes A case of abiraterone acetate withdrawal Eur Urol 64 2013 517 518
2. H. Gauthier, G. Bousquet, D. Pouessel, and S. Culine Abiraterone acetate withdrawal syndrome: does it exist? Case Rep Oncol 5 2012 385 387
3. Z. Culig, and F.R. Santer Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer Steroids 78 2013 851 859
4. A.J. Schrader, M. Boegemann, and C.H. Ohlmann Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone Eur Urol 65 2014 30 36
5. H.S. Soifer, N. Souleimanian, and S. Wu Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells J Biol Chem 287 2012 3777 3787
6. J. Richards, A.C. Lim, and C.W. Hay Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 72 2012 2176 2182
7. Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to 2nd generation anti-androgens enzalutamide and ARN-509. Cancer Discov. In press. http://dx.doi.org/10.1158/2159-8290.CD-13-0226
8. Y. Jiang, J.F. Palma, D.B. Agus, Y. Wang, and M.E. Gross Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer Clin Chem 56 2010 1492 1495